GlaxoSmithKline to ax 850 R&D positions
GlaxoSmithKline (GSK) will eliminate 850 research and development (R&D) positions company-wide, including an undisclosed number in Research Triangle Park, N.C.
The plans announced Wednesday are part of a continuing effort, which began in October 2007 to save $1.4 billion a year over the next three years, according to News & Observer.
An undetermined number of the positions the company expects to cut currently are unfilled, the company said. The London-based GSK has more than 15,000 R&D staffers globally, including 2,500 in Research Triangle Park—one of the company’s two U.S. headquarters.
The majority of the job cuts involve scientists, but administrative staff also will be affected, according to G&K.
The plans announced Wednesday are part of a continuing effort, which began in October 2007 to save $1.4 billion a year over the next three years, according to News & Observer.
An undetermined number of the positions the company expects to cut currently are unfilled, the company said. The London-based GSK has more than 15,000 R&D staffers globally, including 2,500 in Research Triangle Park—one of the company’s two U.S. headquarters.
The majority of the job cuts involve scientists, but administrative staff also will be affected, according to G&K.